Compugen & Merck Serono Establish Novel Biomarker Company

Neviah Genomics is a new company being created by Compugen and Merck Serono.

Israeli biotech company Compugen Ltd and Swiss biopharmaceutical firm Merck Serono have teamed up to establish a new start-up company specialising in the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

Neviah Genomics will operate within the framework of the Merck Serono Israel Bioincubator programme, with Merck Serono Ventures providing the initial funding for the project.

It will use the programme's state-of-the-art facilities, which were inaugurated just last month (May 2012).

Financial details of the agreement have not been disclosed, but Compugen will receive an equity partnership in the new company, along with rights to royalties from any future